OKYO Reconciled Depreciation from 2010 to 2024

OKYO Stock  USD 1.03  0.04  3.74%   
OKYO Pharma Reconciled Depreciation yearly trend continues to be very stable with very little volatility. Reconciled Depreciation is likely to grow to 4,562 this year. During the period from 2010 to 2024, OKYO Pharma Reconciled Depreciation quarterly data regression pattern had sample variance of 8.2 M and median of  167.00. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
3.9 K
Current Value
4.6 K
Quarterly Volatility
2.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check OKYO Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OKYO Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 K, Interest Expense of 1.1 M or Selling And Marketing Expenses of 1.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0407 or Days Sales Outstanding of 0.0. OKYO financial statements analysis is a perfect complement when working with OKYO Pharma Valuation or Volatility modules.
  
Check out the analysis of OKYO Pharma Correlation against competitors.

Latest OKYO Pharma's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of OKYO Pharma Ltd over the last few years. It is OKYO Pharma's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OKYO Pharma's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

OKYO Reconciled Depreciation Regression Statistics

Arithmetic Mean2,052
Geometric Mean618.59
Coefficient Of Variation139.80
Mean Deviation2,262
Median167.00
Standard Deviation2,869
Sample Variance8.2M
Range9.9K
R-Value0.66
Mean Square Error5M
R-Squared0.43
Significance0.01
Slope422.85
Total Sum of Squares115.2M

OKYO Reconciled Depreciation History

2024 4562.06
2023 3866.0
2022 3797.0
2021 2331.0
202010 K
2019 4702.0

About OKYO Pharma Financial Statements

OKYO Pharma investors utilize fundamental indicators, such as Reconciled Depreciation, to predict how OKYO Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Reconciled Depreciation3.9 K4.6 K

Pair Trading with OKYO Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with OKYO Stock

  0.77ME 23Andme HoldingPairCorr

Moving against OKYO Stock

  0.59VCYT VeracytePairCorr
  0.56A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr
  0.48VERA Vera TherapeuticsPairCorr
  0.43DMAC DiaMedica TherapeuticsPairCorr
  0.36DNLI Denali TherapeuticsPairCorr
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:
Check out the analysis of OKYO Pharma Correlation against competitors.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.57)
Return On Assets
(2.92)
Return On Equity
(29.69)
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.